Predict your next investment

SMBC Venture Capital company logo
Corporate Venture
FINANCE | Investment Firms & Funds
smbc-vc.co.jp

See what CB Insights has to offer

Investments

516

Portfolio Exits

56

Funds

10

About SMBC Venture Capital

SMBC Venture Capital is the investment arm of Sumitomo Mitsui Banking Corp.

SMBC Venture Capital Headquarter Location

13-12 Sakura Nihonbashi Building

Tokyo, 103-0025,

Japan

03-6231-1580

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

SMBC Venture Capital Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

SMBC Venture Capital Rank

Research containing SMBC Venture Capital

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned SMBC Venture Capital in 1 CB Insights research brief, most recently on Nov 4, 2019.

Latest SMBC Venture Capital News

Cellusion Raises 1.1B JPY to Advance Japan and Global Clinical Trials of CLS001 for Corneal Endothelial Cell Regenerative Therapy

Jan 7, 2022

January 06, 2022 07:00 PM Eastern Standard Time TOKYO--( BUSINESS WIRE )-- Cellusion Inc. , a regenerative medicine startup aiming to solve the global Corneal transplant waiting list problem with a unique differentiation induction method from iPS cells to Corneal Endothelial Cell Substitute from iPS Cells (CECSi Cells) for bullous keratopathy novel treatment (PJ code: CLS001), today announced it has completed a 1.1 billion yen fundraising round led by existing investors DBJ Capital, Keio Innovation Initiative, and SMBC Venture Capital and new investors Gemseki, Toho Holding, Toyo Seikan Group Holdings and University of Tokyo Edge Capital Partners. The new round brings Cellusion’s total funding in the past year to 1.7 billion yen. [Use of the Funding] Cellusion will use the funding to prepare for the company-sponsored phase 1/2 clinical trials of CLS001 in Japan and overseas, enlarge both of its Tokyo-based research and business teams, and proceed with R&D activities of other pipelines. In addition, by promoting business cooperation with Toho Holdings, Japan-based pharmaceutical wholesaler, and Toyo Seikan Group Holdings, a Japanese multinational conglomerate packaging materials manufacturer, to build the supply chain of CLS001. Cellusion will enhance its efforts to deliver CLS001 for bullous keratopathy patients all over the world. [About CLS001] In spite of the fact that more than 13 million waiting patients for potential blinding diseases such as Bullous Keratopathy, which can only be prevented by corneal transplantation, only about 180,000 corneal transplants are performed annually worldwide. The reason for such a large medical supply-demand gap generated is because current treatments require donor corneas, skilled corneal transplant ophthalmologists, and Eye Banks. Cellusion is developing CLS001, CECSi cells for Corneal Endothelial regeneration to cure Bullous Keratopathy which is applied more than half of all cases of corneal transplantation. CLS001 is expected to replace the current supply limitations by combining “CECSi Cells made from iPS cells with excellent proliferative properties” and "a simple injection cell delivery procedure without needs of human expertise.“ The initiation approval of the CLS001 first in human investigator-initiated clinical study has already been obtained from the Keio University Specially Certified Committee for Regenerative Medicine as well as the Health Sciences Council of MHLW, the Ministry of Health, Labor and Welfare of Japan in July 2021. Keio University and Cellusion are scheduled to start the study at Keio University Hospital as soon as it is ready. [About Cellusion Inc.] Cellusion is a regenerative medicine startup born from the Department of Ophthalmology, Keio University School of Medicine in 2015. Cellusion aims to contribute to the improvement of health and well-being around the world by solving unmet medical needs in medicine with its cutting-edge cell therapy technologies, including a unique differentiation induction method from iPS cells to CECSi Cells. Cellusion’s mission is to a community the clear vision of the future with cellular technology breakthrough. Company: Cellusion Inc.

SMBC Venture Capital Investments

516 Investments

SMBC Venture Capital has made 516 investments. Their latest investment was in Mov as part of their Series A on May 5, 2022.

CBI Logo

SMBC Venture Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/24/2022

Series A

Mov

$5.53M

No

2

5/23/2022

Series B

DoctorMate

$7.84M

Yes

1

5/12/2022

Seed VC

Definer

$0.51M

Yes

1

4/26/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

4/21/2022

Seed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/24/2022

5/23/2022

5/12/2022

4/26/2022

4/21/2022

Round

Series A

Series B

Seed VC

Series A

Seed VC - II

Company

Mov

DoctorMate

Definer

Subscribe to see more

Subscribe to see more

Amount

$5.53M

$7.84M

$0.51M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

1

1

10

10

SMBC Venture Capital Portfolio Exits

56 Portfolio Exits

SMBC Venture Capital has 56 portfolio exits. Their latest portfolio exit was GROOVE X on March 15, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/15/2022

Acquired

1

3/14/2022

Acquired

1

3/1/2022

Acquired

2

12/23/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/26/2021

Acquired

Subscribe to see more

Subscribe to see more

10

Date

3/15/2022

3/14/2022

3/1/2022

12/23/2021

10/26/2021

Exit

Acquired

Acquired

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

1

2

10

10

SMBC Venture Capital Acquisitions

1 Acquisition

SMBC Venture Capital acquired 1 company. Their latest acquisition was Collabos on June 30, 2011.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/30/2011

Other

$99M

Management Buyout

1

Date

6/30/2011

Investment Stage

Other

Companies

Valuation

$99M

Total Funding

Note

Management Buyout

Sources

1

SMBC Venture Capital Fund History

10 Fund Histories

SMBC Venture Capital has 10 funds, including Next Generation Corporate Growth Support I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/29/2017

Next Generation Corporate Growth Support I

Early-Stage Venture Capital

Open

$8.72M

1

12/31/2016

SMBC VC 3

Early-Stage Venture Capital

Closed

1

12/31/2014

SMBC VC 2

Early-Stage Venture Capital

Closed

1

6/6/2012

SMBC Business Development II

Subscribe to see more

Subscribe to see more

10

7/22/2011

SMBC VC 1

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

3/29/2017

12/31/2016

12/31/2014

6/6/2012

7/22/2011

Fund

Next Generation Corporate Growth Support I

SMBC VC 3

SMBC VC 2

SMBC Business Development II

SMBC VC 1

Fund Type

Early-Stage Venture Capital

Early-Stage Venture Capital

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Open

Closed

Closed

Subscribe to see more

Subscribe to see more

Amount

$8.72M

$99M

Sources

1

1

1

10

10

SMBC Venture Capital Team

3 Team Members

SMBC Venture Capital has 3 team members, including current Chief Executive Officer, President, Kohei Katsukawa.

Name

Work History

Title

Status

Kohei Katsukawa

Chief Executive Officer, President

Current

Daiji Furuta

Managing Director

Current

Masahiro Yamaguchi

Managing Director

Current

Name

Kohei Katsukawa

Daiji Furuta

Masahiro Yamaguchi

Work History

Title

Chief Executive Officer, President

Managing Director

Managing Director

Status

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.